Elevance Health, Inc. (ELV) Stock Price & Analysis
Elevance Health, Inc. (ELV) fell 0.43% to USD 377.68 as of July 25, 2026 at 01:13 UTC, according to Nexqual real-time market data.
ELV last closed at USD 379.31; the session ranged USD 375.91–382.79 on volume of 734,833 shares. Market capitalization is $81.91B, with a 52-week range of USD 273.71–436.24 (NYQ). Source: Nexqual, July 25, 2026 at 01:13 UTC.
Key Statistics (as of July 25, 2026 at 01:13 UTC)
| Price | USD 377.68 |
|---|---|
| Change | ▼ 0.43% (down) |
| Previous Close | USD 379.31 |
| Open | USD 380.56 |
| Day Range | USD 375.91 – 382.79 |
| 52-Week Range | USD 273.71 – 436.24 |
| Volume | 734,833 shares |
| Market Cap | $81.91B |
| Exchange | NYQ |
Technical Analysis (ELV)
Nexqual's technical model rates ELV "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 01:13 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.34 (neutral) |
| vs SMA50 | Below (USD 398.48) |
| MACD | -4.29 (negative) |
Analyst Ratings (ELV)
Wall Street analysts rate ELV "Buy" based on 21 analysts, with a mean price target of USD 449.1 (range USD 393–492), per Nexqual as of July 25, 2026 at 01:13 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 449.1 |
| High Target | USD 492 |
| Low Target | USD 393 |
| Buy / Hold / Sell | 15 / 7 / 0 |
Earnings (ELV)
| Next Earnings Date | 2026-10-21 |
|---|---|
| EPS Estimate | USD 4.66 |
| Revenue Estimate | $49.12B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 7.45 vs est 6.21 ▲ beat |
| 2026-03-31 | USD 12.58 vs est 10.81 ▲ beat |
| 2025-12-31 | USD 3.33 vs est 3.09 ▲ beat |
| 2025-09-30 | USD 6.03 vs est 4.94 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financials & Fundamentals (ELV)
| Total Revenue | $201.11B |
|---|---|
| Revenue Growth (YoY) | +1.40% |
| Gross Margin | +25.99% |
| Operating Margin | +4.56% |
| Profit Margin | +2.47% |
| ROE | +11.13% |
| Debt / Equity | 68.95 |
| Current Ratio | 1.52 |
| Total Cash | $37.51B |
| Total Debt | $31.04B |
| Free Cash Flow | $4.31B |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Financial Health Score (ELV)
Nexqual rates Elevance Health, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:13 UTC.
| Growth | Solid — Revenue +13% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 26%, operating 5% |
| Balance Sheet | Solid — $37.5B cash vs $31.0B debt, net cash position |
| Cash Flow | Mixed — FCF $4.31B, slim 2.2% margin |
| Efficiency | Mixed — ROE 11%, ROA 3.8% |
Ownership (ELV)
| Insider Ownership | +0.19% |
|---|---|
| Institutional Ownership | +93.77% |
| Shares Outstanding | 216.87M |
| Float | 216.41M |
| Short % of Float | +3.10% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
Leadership (ELV)
Elevance Health, Inc. is led by Gail Koziara Boudreaux (age 64), President, CEO & Director, per Nexqual as of July 25, 2026 at 01:13 UTC.
| President, CEO & Director | Gail Koziara Boudreaux (age 64) |
|---|---|
| Executive VP & CFO | Mark Bradley Kaye (age 45) |
| EVP and President of Commercial & Specialty Health Benefits | Charles Morgan Kendrick (age 59) |
| Vice President of Investor Relations | Nathan Allen Rich |
| Senior Vice President of Public Affairs | Julie Goon |
Major Backers & Investors (ELV)
Notable institutional backers of Elevance Health, Inc. include Wellington Management, Sanders Capital, LLC, Artisan Partners Limited Partnership, according to Nexqual as of July 25, 2026 at 01:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 3.79% |
| Sanders Capital, LLC | 2.72% |
| Artisan Partners Limited Partnership | 2.36% |
| Invesco | 2.22% |
| Harris Associates L.P. | 2.21% |
| First Eagle Funds-First Eagle Global Fund | 1.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.46% |
| BlackRock | 10.51% |
| State Street | 5.95% |
| Geode Capital | 2.39% |
Source: Nexqual, July 25, 2026 at 01:13 UTC.
From Elevance Health, Inc.'s Latest SEC 10-K Filing (filed 2026-02-06)
Key Strengths & Strategy (as disclosed to the SEC)
- Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States.
- The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.
- It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits.
- The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MOH | Molina Healthcare Inc | USD 197.55 | ▼ 10.91% |
| HUM | Humana Inc. | USD 389.32 | ▼ 2.08% |
| CNC | Centene Corporation | USD 63.41 | ▼ 3.76% |
| CI | The Cigna Group | USD 289.57 | ▲ 1.66% |
| HCA | HCA Healthcare, Inc. | USD 382.19 | ▲ 2.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:13 UTC. This page is informational and not investment advice.